Neuroendocrine differentiation in male breast carcinomas

The presence of neuroendocrine differentiation, as expressed by cellular chromogranin immunoreactivity, was investigated in paraffin‐embedded tissue material from 51 consecutive cases of male breast carcinoma. From six of these cases electron microscopic studies were included. Chromogranin‐immunoreactive cells were present in solid cords and delineated tubular structures. Ultrastructurally, dense core secretory granules could be detected. The expression of neuroendocrine differentiation was 45%, which is between two and eight times higher than reported for female breast carcinomas by other investigators. The present findings suggest that male breast carcinoma is an exclusive tumour disease showing both similarities and discrepancies when compared to its female counterpart.

[1]  L. Deftos.  Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker. , 1991, Endocrine reviews.

[2]  R. W. Crichlow,et al.  Male breast cancer. , 1990, The Surgical clinics of North America.

[3]  M. Papotti,et al.  Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. , 1989, Seminars in diagnostic pathology.

[4]  J. Nesland,et al.  Neuroendocrine differentiation in breast lesions. , 1988, Pathology, research and practice.

[5]  E. Brambilla,et al.  Isoenzyme pattern of enolase in the diagnosis of neuroendocrine bronchopulmonary tumors , 1987, Cancer.

[6]  P. Camilli,et al.  Regulated Secretory Pathways of Neurons and Their Relation to the Regulated Secretory Pathway of Endocrine Cells , 1987 .

[7]  P. Greengard,et al.  Protein p38: an integral membrane protein specific for small vesicles of neurons and neuroendocrine cells , 1986, The Journal of cell biology.

[8]  T. Bauer,et al.  Partial mastectomy: pathologic findings and prognosis. , 1986, Human pathology.

[9]  J. Nesland,et al.  Neurone specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations , 1986, The Journal of pathology.

[10]  T. Anderson,et al.  Distribution of dense core granules in normal, benign and malignant breast tissue , 1985, The Journal of pathology.

[11]  A. Tischler,et al.  Multidirectional differentiation in neuroendocrine neoplasms. , 1984, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  R. Lloyd,et al.  Detection of chromogranin in neuroendocrine cells with a monoclonal antibody. , 1984, The American journal of pathology.

[13]  R. Lloyd,et al.  Specific endocrine tissue marker defined by a monoclonal antibody. , 1983, Science.

[14]  V. Eusebi,et al.  ‘Carcinoid’ tumours of the breast: the morphological spectrum of argyrophil carcinomas , 1982, Histopathology.

[15]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[16]  V. Eusebi,et al.  Endocrine differentiation in mucoid carcinoma of the breast , 1980, Histopathology.

[17]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[18]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[19]  W. Huttner,et al.  Synaptophysin and chromogranins/secretogranins widespread constituents of distinct types of neuroendocrine vesicles and new tools in tumor diagnosis , 1989, Virchows Archiv. B, Cell pathology including molecular pathology.

[20]  I. Andersson,et al.  Breast carcinoma. Aspects of early stages, progression and related problems. , 1980, Acta pathologica et microbiologica Scandinavica. Supplement.